Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCX282-B · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | EXPERIMENTAL | Blinded study arm |
| 4 | EXPERIMENTAL | Blinded study arm |
| Name | Type | Description |
|---|---|---|
| CCX282-B | DRUG | 250mg capsule, twice daily, 13 weeks |
| Placebo | DRUG | Placebo capsule, twice daily, 13 weeks |
Key Inclusion Criteria: * Male or female, between 18 and 75 years of age * Established diagnosis of celiac disease * Subject has been following a strict gluten-free diet for at least 24 months Key Exclusion Criteria: * History of any infection requiring intravenous antibiotics, a serious local in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
CCX282-B is an investigational small molecule being studied for gastrointestinal conditions, including moderate to severe Crohn's disease and celiac disease. It has been evaluated in Phase 2 clinical trials for these indications.
CCX282-B is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical development.
CCX282-B is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for Crohn's disease and celiac disease have been completed.
CCX282-B has been studied in three completed Phase 2 trials. NCT00102921 and NCT00306215 evaluated the drug in moderate to severe Crohn's disease, while NCT00540657 assessed it in celiac disease. These trials were randomized, double-blind, and placebo-controlled.
CCX282-B is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial information.